Skip to main content
Erschienen in: Reactions Weekly 1/2019

01.08.2019 | Case report

Antineoplastics

Cardiomyopathy: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

A 38-year-old man developed acute heart failure following chemotherapy with azacitidine, cytarabine, idarubicin and sorafenib for acute myeloid leukaemia (AML) [dosages, routes and durations of tratments to reactions onset not stated]. …
Literatur
Zurück zum Zitat Georges El-Khoury G, et al. Emerging cardio-oncology therapeutics: The role of ivabradine and levosimendan in acute heart failure reversible toxicity. European Journal of Heart Failure 21 (Suppl. 1): 303 (plus poster) abstr. P1209, May 2019. Available from: URL: http://doi.org/10.1002/ejhf.1488 [abstract] -Lebanon Georges El-Khoury G, et al. Emerging cardio-oncology therapeutics: The role of ivabradine and levosimendan in acute heart failure reversible toxicity. European Journal of Heart Failure 21 (Suppl. 1): 303 (plus poster) abstr. P1209, May 2019. Available from: URL: http://​doi.​org/​10.​1002/​ejhf.​1488 [abstract] -Lebanon
Metadaten
Titel
Antineoplastics
Cardiomyopathy: case report
Publikationsdatum
01.08.2019
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-019-65793-4

Weitere Artikel der Ausgabe 1/2019

Reactions Weekly 1/2019 Zur Ausgabe

Case report

Ethosuximide

Case report

Bevacizumab

Case report

Zinc gluconate

Case report

Perampanel

Case report

Pembrolizumab